All In Biotech

NDA 208845 · Pacira Pharms INC

Zilretta

Triamcinolone Acetonide · Intra-Articular

Last checked: Nov 20, 2026Latest source record: Dec 3, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Oct 6, 2017

Approved uses

2

Original approval plus efficacy supplements

Registered trials

692

135 Phase 3, 52 recruiting

FAERS reports

864

179 serious, 10 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 29, 2026.

ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee. ZILRETTA is an extended-release synthetic corticosteroid indicated as an intra-articular injection for the management of osteoarthritis pain of the knee. ( 1 ) Limitation of Use The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated. ( 2.1 ) Limitation of Use The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated. [see Dosage and Administration (2.1) ] .

Mechanism: Triamcinolone acetonide is a corticosteroid with anti-inflammatory and immunomodulating properties. It binds to and activates the glucocorticoid receptor, leading to activation of anti-inflammatory transcription factors such as lipocortins and inhibition of inflammatory transduction pathways by blocking the release of arachidonic acid and preventing the synthesis of prostaglandins and leukotrienes.

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 23, 2019 Supplement 7 · Efficacy LetterLabel
  • Oct 6, 2017 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • ZILRETTA · TRIAMCINOLONE ACETONIDE 32MG/VIAL · FOR SUSPENSION, EXTENDED RELEASE, INTRA-ARTICULAR · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Triamcinolone Acetonide" as an intervention, any sponsor and status, largest first.

All 692 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • recalled product administered226
  • arthralgia126
  • drug ineffective78
  • no adverse event78
  • joint swelling47
  • therapeutic response shortened44
  • pain41
  • blood glucose increased35
  • headache29
  • arthritis bacterial28
  • off label use27
  • blood pressure increased22

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201836
2019122
202095
202185
202277
202357
2024310
202567
202615

Recalls

2 FDA enforcement reports for this application.

  • Jun 12, 2024 · Class II · Ongoing

    Failed Dissolution Specifications - did not meet the acceptance criteria for IVR Level 3 testing at 9 months 2-8¿C followed by 6 weeks at 25¿C

  • May 7, 2024 · Class II · Ongoing

    Failed Stability Specifications - at 12 months 2-8 degrees C followed by 6 weeks at 25 degrees C.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zilretta (Triamcinolone Acetonide)

2024 spending

$1.9M

Beneficiaries

1,377

2,092 claims

Per beneficiary

$1,408

$644.02 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$682,598
2024$1,939,140

Part B: Zilretta (Triamcinolone Acetonide) · HCPCS J3304

2024 spending

$64.8M

Beneficiaries

51,173

90,238 claims

Per beneficiary

$1,267

2024 ASP limit $17.65 per unit

View as table
YearSpending
2020$51,659,541
2021$63,872,984
2022$62,805,234
2023$62,204,627
2024$64,847,910

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 990 on PubMed

Sponsor: Pacira Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.